|
All(n=105) |
(n=47) |
(n=58) |
|
Male/female(n) |
53/52 |
31/16 |
22/36 |
0.004 |
Age(years) |
62.0(49.0-69.50) |
66.0(54.0-75.0) |
57.5(46.75-65.0) |
0.004 |
Smoking history—No, % |
4(3.8%) |
1(2.1%) |
3(5.2%) |
0.626 |
History of alcohol intake—No, % |
1(1.0%) |
1(2.1%) |
0(0%) |
0.448 |
Symptoms and signs—No, % |
Symptoms and signs—No, % |
Symptoms and signs—No, % |
Symptoms and signs—No, % |
Symptoms and signs—No, % |
Fever on admission |
90(85.7%) |
40(85.1%) |
50(86.2%) |
0.873 |
Nasal congestion |
1(1.0%) |
1(2.1%) |
0(0%) |
0.448 |
Headache |
4(3.8%) |
2(4.3%) |
2(4.3%) |
1.000 |
Cough |
65(61.9%) |
29(61.7%) |
36(62.1%) |
0.969 |
Sore throat |
5(4.8%) |
2(4.3%) |
3(5.2%) |
1.000 |
Sputum production |
30(28.6%) |
12(25.5%) |
18(31.0%) |
0.535 |
Fatigue |
38(36.2%) |
20(42.6%) |
18(31.0%) |
0.222 |
Shortness of breath |
37(35.2%) |
23(48.9%) |
14(24.1%) |
0.008 |
Nausea or vomiting |
7(6.7%) |
4(8.5%) |
3(5.2%) |
0.698 |
Myalgia or arthralgia |
8(7.6%) |
3(6.4%) |
5(8.6%) |
0.729 |
Chill |
7(6.7%) |
6(12.8%) |
1(1.7%) |
0.043 |
Throat congestion |
2(1.9%) |
0(0%) |
2(3.4%) |
0.501 |
Coexisting disorders—No, % |
Coexisting disorders—No, % |
Coexisting disorders—No, % |
Coexisting disorders—No, % |
Coexisting disorders—No, % |
Diabetes |
16(15.2%) |
10(21.3%) |
6(10.3%) |
0.121 |
Hypertension |
23(21.9%) |
14(29.8%) |
9(15.5%) |
0.079 |
Coronary heart disease |
9(8.6%) |
6(12.8%) |
3(5.2%) |
0.293 |
Hepatitis B infection |
2(1.9%) |
2(4.3%) |
0(0%) |
0.198 |
COPD |
1(1.0%) |
1(2.1%) |
0(0%) |
0.448 |
SBP (mmHg) |
129.0(118.0-137.0) |
128.0(118.0-138.0) |
129.0(118.75-135.8) |
0.836 |
DBP (mmHg) |
80.0(73.0-84.0) |
78.0(71.25-85.0) |
80.0(73.0-83.0) |
0.824 |
Heart rate (min) |
85.0(78.0-96.0) |
84.0(78.0-97.0) |
85.0(77.0-93.5) |
0.619 |
Laboratory findings |
Laboratory findings |
Laboratory findings |
Laboratory findings |
Laboratory findings |
WBC (×109/L) |
5.03(3.96-7.04) |
5.59(3.86-8.20) |
4.96(4.03-6.50) |
0.393 |
RBC (×1012/L) |
4.2(3.7-4.6) |
4.1±0.7 |
4.2±0.6 |
0.297 |
Hb (g/L) |
125.0(117.0-140.0) |
128.0±19.4 |
125.0±15.3 |
0.515 |
PLT (×109/L) |
206.0(152.5-261.0) |
176.0(125.0-229.0) |
230.5(178.3-303.3) |
0.001 |
LYM (%) |
22.9(12.9-29.8) |
14.2(6.3-23.5) |
27.2(21.9-35.6) |
<0.001 |
LYM (×109/L) |
1.13±0.5 |
0.79±0.3 |
1.35±0.4 |
<0.001 |
LYM <1.1×109 cells/L |
52(49.5%) |
40(76.9%) |
12(23.1%) |
<0.001 |
ALT (U/L) |
27.0(17.8-43.0) |
24.0(17.0-40.5) |
31.5(19.0-45.3) |
0.384 |
AST (U/L) |
29.0(20.0-42.0) |
31.0(20.0-47.5) |
25.5(20.3-38.0) |
0.289 |
Cr (umol/L) |
60.5(49.0-78.0) |
68.50(53.8-85.8) |
55.50(48.3-68.0) |
0.005 |
eGFR (ml/min) |
99.1(88.0-109.0) |
90.5(59.0-107.22) |
101.2(95.3-109.8) |
0.006 |
UA (umol/L) |
247.5(193.5-332.8) |
253.0(182.0-343.8) |
241.0(203.5-322.5) |
0.817 |
D-D (mg/L) |
0.56(0.34-3.95) |
0.70(0.355-8.19) |
0.54(0.34-3.42) |
0.508 |
K (mmol/L) |
4.1(3.6-4.4) |
4.1(3.5-4.4) |
4.1(3.7-4.4) |
0.521 |
Na (mmol/L) |
142.0(139.0-145.0) |
141.5(139.0-146.0) |
142.0(140.0-145.0) |
0.795 |
Cl (mmol/L) |
105.0(102.7-108.1) |
104.3(103.1-108.3) |
105.5(102.1-108.1) |
0.646 |
TC (mmol/L) |
3.64(3.27-4.32) |
3.50(3.09-4.03) |
3.84(3.41-4.52) |
0.016 |
TG (mmol/L) |
1.19(0.90-1.69) |
1.23(0.95-1.63) |
1.15(0.86-1.93) |
0.983 |
HDL (mmol/L) |
0.90(0.76-1.06) |
0.90±0.338 |
0.90±0.234 |
0.285 |
LDL (mmol/L) |
2.26(1.87-2.74) |
2.10(1.74-2.60) |
2.40(2.02-2.97) |
0.031 |
CD3 cells count |
706.0(459.5-921.0) |
437.0(224.0-606.0) |
881.5(760.8-1034.2) |
<0.001 |
CD4 cells count |
437.0(268.5-561.0) |
240.0(123.0-325.0) |
546.5(475.0-651.5) |
<0.001 |
CD8 cells count |
241.0(131.0-333.5) |
153.0(64.0-242.0) |
293.0(226.75-424.3) |
<0.001 |
CD4/CD8 |
1.76(1.31-2.29) |
1.60(1.11-1.96) |
1.88(1.44-2.64) |
0.014 |
Abnormalities on chest CT—No,% |
Abnormalities on chest
CT—No,% |
Abnormalities on chest CT—No,% |
Abnormalities
on chest CT—No,% |
Abnormalities on chest
CT—No,% |
Ground-glass opacity |
50(47.6%) |
18(38.3%) |
32(55.2%) |
0.085 |
Local patchy shadowing |
32(30.5%) |
9(19.1%) |
23(39.7%) |
0.023 |
Treatment |
Treatment |
Treatment |
Treatment |
Treatment |
Oxygen inhalation |
85(81.0%) |
42(93.3%) |
43(78.2%) |
0.035 |
Mechanical ventilation |
10(9.5%) |
8(17.4%) |
2(3.7%) |
0.041 |
Glucocorticoids |
42(40.0%) |
26(53.1%) |
23(39.7%) |
0.110 |
Antiviral treatment |
103(98.1%) |
46(97.9%) |
57(98.3%) |
1.000 |
Intravenous immunoglobulin |
49(46.7%) |
26(55.3%) |
23(39.7%) |
0.110 |
Antibiotic treatment |
77(73.3%) |
40(85.1%) |
37(63.8%) |
0.014 |
Antifungal treatment |
5(4.8%) |
3(6.4%) |
2(3.4%) |
0.655 |
Clinical outcome |
Clinical outcome |
Clinical outcome |
Clinical
outcome |
Clinical outcome |
Death (No,%) |
22(21.0%) |
20(42.6%) |
2(3.4%) |
<0.001 |